WEKO3
アイテム
{"_buckets": {"deposit": "d1213cba-7701-4095-978e-bf8da0e4dd67"}, "_deposit": {"created_by": 2, "id": "14564", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "14564"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00014564", "sets": ["11"]}, "author_link": ["53545", "53550", "53549", "53546", "53540", "53542", "53541", "53548", "53538", "53543", "53536", "53547", "53537", "53539", "53544"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2010", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "20", "bibliographicPageEnd": "2218", "bibliographicPageStart": "2211", "bibliographicVolumeNumber": "49", "bibliographic_titles": [{"bibliographic_title": "Internal Medicine"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objective Mizoribine (MZR) is an immunosuppressant that inhibits nucleic acid metabolism and is a relatively safe disease-modifying anti-rheumatic drug (DMARD). We evaluated the efficacy and safety of one single dose per day for patients with rheumatoid arthritis (RA). Patients and Methods In this study 32 patients with RA received MZR therapy. We evaluated the average dose of MZR and prednisolone, response to treatment and peak plasma level of MZR. Results The average dose of MZR was 146.1±31.2 (range: 50-200) mg/day. The average dose of prednisolone was 4.63±3.59 (range: 0-14) mg/day. The average plasma level of MZR, measured after 3 hours, was 2.20±0.49 μg/mL in the responder group and 1.59±0.82 μg/mL in the non-responder group (p=0.020). The treatment with MZR for 24 weeks was completed by 71.9% of patients and the proportion of patients who achieved a good and moderate response rate according to the European League Against Rheumatism (EULAR) criteria was 56.3% at 24 weeks. The plasma level of MZR which was greater than or equal to 2.12 μg/ mL was significantly correlated with the clinical response (p\u003c0.01). Only one of thirty-two cases discontinued the treatment, because of skin eruption. Conclusion This study included patients that could not be treated with other DMARDs and/or biologic agents because of age, interstitial pneumonia and other complications. We show that MZR may be a useful and relatively safe therapy for patients in this group.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Internal Medicine, 49(20), pp.2211-2218; 2010", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "The Japanese Society of Internal Medicine"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.2169/internalmedicine.49.3810", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright (c) 2010 by The Japanese Society of Internal Medicine"}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10827774", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "09182918", "subitem_source_identifier_type": "ISSN"}]}, "item_2_text_62": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "日本内科学会"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ichinose, Kunihiro"}], "nameIdentifiers": [{"nameIdentifier": "53536", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Origuchi, Tomoki"}], "nameIdentifiers": [{"nameIdentifier": "53537", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawashiri, Shin-ya"}], "nameIdentifiers": [{"nameIdentifier": "53538", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iwamoto, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "53539", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujikawa, Keita"}], "nameIdentifiers": [{"nameIdentifier": "53540", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aramaki, Toshiyuki"}], "nameIdentifiers": [{"nameIdentifier": "53541", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamachi, Makoto"}], "nameIdentifiers": [{"nameIdentifier": "53542", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Arima, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "53543", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tamai, Mami"}], "nameIdentifiers": [{"nameIdentifier": "53544", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Hideki"}], "nameIdentifiers": [{"nameIdentifier": "53545", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ida, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "53546", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawakami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "53547", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsukada, Toshiaki"}], "nameIdentifiers": [{"nameIdentifier": "53548", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ueki, Yukitaka"}], "nameIdentifiers": [{"nameIdentifier": "53549", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Eguchi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "53550", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "IntMed49_2211.pdf", "filesize": [{"value": "405.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 405300.0, "url": {"label": "IntMed49_2211.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/14564/files/IntMed49_2211.pdf"}, "version_id": "274d3e3e-bf47-4035-ad41-e29b93234040"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Mizoribine (MZR)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Plasma level", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Rheumatoid arthritis (RA)", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Efficacy and Safety of Mizoribine by One Single Dose Administration for Patients with Rheumatoid Arthritis", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Efficacy and Safety of Mizoribine by One Single Dose Administration for Patients with Rheumatoid Arthritis"}]}, "item_type_id": "2", "owner": "2", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/24559", "pubdate": {"attribute_name": "公開日", "attribute_value": "2011-01-13"}, "publish_date": "2011-01-13", "publish_status": "0", "recid": "14564", "relation": {}, "relation_version_is_last": true, "title": ["Efficacy and Safety of Mizoribine by One Single Dose Administration for Patients with Rheumatoid Arthritis"], "weko_shared_id": 2}
Efficacy and Safety of Mizoribine by One Single Dose Administration for Patients with Rheumatoid Arthritis
http://hdl.handle.net/10069/24559
http://hdl.handle.net/10069/2455934757807-0546-415a-bb20-7f875741d709
名前 / ファイル | ライセンス | アクション |
---|---|---|
IntMed49_2211.pdf (405.3 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2011-01-13 | |||||
タイトル | ||||||
タイトル | Efficacy and Safety of Mizoribine by One Single Dose Administration for Patients with Rheumatoid Arthritis | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Mizoribine (MZR) | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Plasma level | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Rheumatoid arthritis (RA) | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ichinose, Kunihiro
× Ichinose, Kunihiro× Origuchi, Tomoki× Kawashiri, Shin-ya× Iwamoto, Naoki× Fujikawa, Keita× Aramaki, Toshiyuki× Kamachi, Makoto× Arima, Kazuhiko× Tamai, Mami× Nakamura, Hideki× Ida, Hiroaki× Kawakami, Atsushi× Tsukada, Toshiaki× Ueki, Yukitaka× Eguchi, Katsumi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objective Mizoribine (MZR) is an immunosuppressant that inhibits nucleic acid metabolism and is a relatively safe disease-modifying anti-rheumatic drug (DMARD). We evaluated the efficacy and safety of one single dose per day for patients with rheumatoid arthritis (RA). Patients and Methods In this study 32 patients with RA received MZR therapy. We evaluated the average dose of MZR and prednisolone, response to treatment and peak plasma level of MZR. Results The average dose of MZR was 146.1±31.2 (range: 50-200) mg/day. The average dose of prednisolone was 4.63±3.59 (range: 0-14) mg/day. The average plasma level of MZR, measured after 3 hours, was 2.20±0.49 μg/mL in the responder group and 1.59±0.82 μg/mL in the non-responder group (p=0.020). The treatment with MZR for 24 weeks was completed by 71.9% of patients and the proportion of patients who achieved a good and moderate response rate according to the European League Against Rheumatism (EULAR) criteria was 56.3% at 24 weeks. The plasma level of MZR which was greater than or equal to 2.12 μg/ mL was significantly correlated with the clinical response (p<0.01). Only one of thirty-two cases discontinued the treatment, because of skin eruption. Conclusion This study included patients that could not be treated with other DMARDs and/or biologic agents because of age, interstitial pneumonia and other complications. We show that MZR may be a useful and relatively safe therapy for patients in this group. | |||||
書誌情報 |
Internal Medicine 巻 49, 号 20, p. 2211-2218, 発行日 2010 |
|||||
出版者 | ||||||
出版者 | The Japanese Society of Internal Medicine | |||||
出版者別言語 | ||||||
日本内科学会 | ||||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 09182918 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA10827774 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.2169/internalmedicine.49.3810 | |||||
権利 | ||||||
権利情報 | Copyright (c) 2010 by The Japanese Society of Internal Medicine | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Internal Medicine, 49(20), pp.2211-2218; 2010 |